ALOX5AP and ovarian carcinoma: Additionally, we assessed survival rate of correlation to ALOX5AP based on different ovarian cancer stages, we found that elevated ALOX5AP expression significantly predicted worse OS and PFS in stage 3-4 patients (p < 0.05; Figure 2F) but not in stage 1-2 patients (p > 0.05; data not shown).